Hologic (NASDAQ:HOLX) Issues Quarterly Earnings Results, Hits Estimates

Hologic (NASDAQ:HOLX) announced its quarterly earnings data on Monday. The medical equipment provider reported $1.01 EPS for the quarter, hitting analysts’ consensus estimates of $1.01, Briefing.com reports. Hologic had a return on equity of 20.11% and a net margin of 19.59%. The firm had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same period last year, the company earned $0.89 earnings per share. The company’s revenue was up 4.5% on a year-over-year basis.

Hologic Stock Performance

Shares of HOLX opened at $80.49 on Thursday. The firm has a market cap of $18.70 billion, a P/E ratio of 24.17, a PEG ratio of 3.03 and a beta of 0.98. Hologic has a twelve month low of $66.93 and a twelve month high of $84.67. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99. The firm’s 50 day moving average price is $81.05 and its two-hundred day moving average price is $78.12.

Analyst Ratings Changes

A number of research firms recently weighed in on HOLX. Royal Bank of Canada boosted their price target on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research note on Tuesday. Needham & Company LLC reiterated a “buy” rating and set a $90.00 target price on shares of Hologic in a research report on Tuesday, October 15th. Stephens restated an “overweight” rating and issued a $92.00 price target on shares of Hologic in a research report on Tuesday, July 30th. StockNews.com downgraded Hologic from a “buy” rating to a “hold” rating in a report on Wednesday. Finally, JPMorgan Chase & Co. raised their target price on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a report on Tuesday. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Hologic currently has an average rating of “Moderate Buy” and a consensus price target of $89.25.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.